Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity.
Sign Up to like & getrecommendations! Published in 2025 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-25-0171
Abstract: Claudin18.2 (CLDN18.2)-targeted chimeric antigen receptor T (CAR-T) cell therapy has shown promising antitumor activity in gastrointestinal cancers. However, limited persistence in solid tumors and on-target off-tumor (OTOT) toxicity remain significant challenges. Here, we report on… read more here.
Keywords: cldn18; imc002; toxicity; car ... See more keywords